Navigation Links
Vidaza receives positve opinion from European CHMP
Date:10/27/2008

The Aplastic Anemia & MDS International Foundation is pleased to inform patients that the European Committee for Medicinal Products for Human Use (CHMP) has awarded Vidaza (azacitidine) a positive opinion for the treatment of myelodysplastic syndromes (MDS) patients who are not eligible for stem cell transplants.

The CHMP's positive opinion is based on data from the AZA-001 trial, which demonstrated an overall, unprecedented survival benefit for higher-risk MDS patients. The positive opinion will be forwarded to the European Commission that generally follows the recommendation of the CHMP and issues final marketing approval.

"We are excited by Vidaza's positive CHMP opinion because there are few treatment options for patients in Europe with this disease," said John Huber, Executive Director of the Aplastic Anemia & MDS International Foundation, "Vidaza not only extends patients' lives, but also improves their quality of life. We are hopeful that Vidaza will receive marketing approval shortly and quickly be available for patients across Europe."

Myelodysplastic syndromes (MDS) occur when the bone marrow stem cells malfunction. This results in the production of too many defective blood cells and not enough normal cells. Diagnosis is made through blood tests and a bone marrow biopsy. Once diagnosed, treatment and evaluation should occur under the care of a hematologist or hematologists/oncologist. There are many subtypes of MDS classified according to how the disease manifests itself in the blood and marrow of the patient. Treatments include blood transfusions, growth factors, chemotherapy and bone marrow transplant.


'/>"/>

Contact: John Huber
huber@aamds.org
301-279-7202
Aplastic Anemia & MDS International Foundation
Source:Eurekalert

Page: 1

Related biology news :

1. The MDS Foundation supports the FDAs decision to expand vidaza label to include survival data
2. FDA approves Vidaza label expansion
3. Global Viral Forecasting Initiative receives $11M to implement pandemic early warning system
4. Penn State receives new NASA astrobiology grant
5. American College of Medical Genetics receives $13.5M NIH contract
6. Kount Receives Patent for Device Fingerprinting
7. L-1 Identity Solutions Receives $5.9 Million Drivers License Contract Expansion from the State of Mississippi
8. Wistar Institute researcher receives New Innovator award from NIH
9. CCNY receives $5 million NSF grant to establish center for nanostructure applications
10. NYU receives $490k NSF grant to promote women in the sciences
11. Childrens National researcher receives ACCP Distinguished Investigator Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , June 27, 2016  Sequenom, Inc. (NASDAQ: ... enabling healthier lives through the development of innovative products ... the United States denied its ... the claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 ... criteria established by the Supreme Court,s Mayo Collaborative Services ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of ... their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been ... Target to its list of well-respected retailers. This list includes such fine stores ...
Breaking Biology Technology: